Fukuda Keisuke, Hasegawa Seiji, Kawamura Tomonori, Waratani Naoto, Hirata Kumiko, Higashimori Akihiro, Yokoi Yoshiaki
Department of Cardiology, Kishiwada Tokushukai Hospital, 4-27-1 Kamori-cho, Kishiwada, Osaka, 596-8522, Japan.
Department of Medical Science, Osaka Educational University, Osaka, Japan.
ESC Heart Fail. 2021 Apr;8(2):1590-1595. doi: 10.1002/ehf2.13266. Epub 2021 Feb 19.
In patients with heart failure, over-activation of the cardiac sympathetic nerve (CSN) function is associated with severity of heart failure and worse outcome. The effects of MitraClip therapy on the CSN activity in patients with mitral regurgitation (MR) remained unknown. In this study, we evaluated the impact of the MitraClip therapy on CSN activity assessed by I-metaiodobezylguanidine (MIBG) scintigraphy.
We enrolled consecutive patients with moderate-to-severe (3+) or severe (4+) MR who were scheduled to undergo MitraClip procedure in this prospective observational study. MIBG scintigraphy was performed at baseline and 6 months after the MitraClip procedure to evaluate the heart-mediastinum ratio and washout rate (WR). Changes in these MIBG parameters were analysed. Of the 13 consecutive patients, 10 were successfully treated with MitraClip procedure and completed follow-up assessment. With regard to the MIBG parameters, changes in the early and delayed heart-mediastinum ratio from baseline to 6 months were not significant (2.16 ± 0.42 to 2.06 ± 0.34, P = 0.38 and 1.87 ± 0.39 to 1.83 ± 0.39, P = 0.43, respectively), whereas WR was significantly decreased (38.6 ± 3.9% to 32.6 ± 3.94%, P = 0.002).
The CSN activity of the WR on MIBG imaging was improved 6 months after MitraClip therapy in patients with 3+ or 4+ MR.
在心力衰竭患者中,心脏交感神经(CSN)功能的过度激活与心力衰竭的严重程度及更差的预后相关。MitraClip治疗对二尖瓣反流(MR)患者CSN活性的影响尚不清楚。在本研究中,我们评估了MitraClip治疗对通过碘-间位碘代苄胍(MIBG)闪烁显像评估的CSN活性的影响。
在这项前瞻性观察研究中,我们纳入了计划接受MitraClip手术的中重度(3+)或重度(4+)MR的连续患者。在基线时和MitraClip手术后6个月进行MIBG闪烁显像,以评估心纵隔比和洗脱率(WR)。分析这些MIBG参数的变化。在这13例连续患者中,10例成功接受了MitraClip手术并完成了随访评估。关于MIBG参数,从基线到6个月时早期和延迟心纵隔比的变化不显著(分别为2.16±0.42至2.06±0.34,P = 0.38;1.87±0.39至1.83±0.39,P = 0.43),而WR显著降低(38.6±3.9%至32.6±3.94%,P = 0.002)。
在3+或4+ MR患者中,MitraClip治疗6个月后,MIBG显像上WR的CSN活性得到改善。